Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib

Biomedical Chromatography

Volumn 27, Issue 3, 2013, Pages 335-342

  Birch, M ^a   Morgan, P E ^a   Handley, S ^a   Ho, A ^a   Ireland, R ^a   Flanagan, R J ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic myeloid leukaemia; Dasatinib; Imatinib; Norimatinib; Therapeutic drug monitoring

Indexed keywords

BLOOD; DRUG PRODUCTS; MASS SPECTROMETRY; PATIENT MONITORING;

CHRONIC MYELOID LEUKEMIAS; DASATINIB; HPLC METHOD; IMATINIB; LC-MS-MS; NORIMATINIB; SIMPLE++; THERAPEUTIC DRUG MONITORING; TYROSINE KINASE INHIBITOR; WHOLE BLOOD;

AMINO ACIDS;

AMMONIUM ACETATE; DASATINIB; EDETIC ACID; IMATINIB; NORIMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; PH MEASUREMENT; QUALITY CONTROL; TANDEM MASS SPECTROMETRY; ULTRAVIOLET RADIATION;

EID: 84873257263     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2796     Document Type: Article

References (37)

1. Abbott BL. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. Clinical Therapeutics 2012; 34: 272-281.
2. Bonfiglio R, King RC, Olah TV and Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Communications in Mass Spectrometry 1999; 13: 1175-1185.
3. Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, Titier K and Molimard M. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clinica Chimica Acta 2011; 412: 1060-1067.
4. Buclin T, Widmer N, Biollaz J and Decosterd LA. Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. The Lancet Oncology 2011; 12: 9-11.
5. Couchman L, Birch M, Ireland R, Corrigan A, Wickramasinghe S, Josephs D, Spicer J and Flanagan RJ. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry 2012; 403: 1685-1695.
6. D'Avolio A, Simiele M, De Francia S, Ariaudo A, Baietto L, Cusato J, Fava C, Saglio G, Di Carlo F and Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). Journal of Pharmaceutical and Biomedical Analysis 2012; 59: 109-116.
7. Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J and Jaehde U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clinical Pharmacokinetics 2011; 50: 551-603.
8. Faber E, Friedecký D, Micová K, Divoká M, Katrincsáková B, Rozmanová S, Jarosová M, Indrák K and Adam T. Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response. International Journal of Hematology 2010; 91: 897-902.
9. Faber E, Friedecký D, Mičová K, Rožmanová S, Divoká M, Jarošová M, Indrák K and Adam T. Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting. Annals of Hematology 2012; 91: 923-929.
10. FDA/CDER. Guidance for Industry. Bioanalytical Method Validation. Food and Drug Administration/Center for Drug Evaluation and Research, 2001. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf (accessed 6 January 2012).
11. Furlong MT, Agrawal S, Hawthorne D, Lago M, Unger S, Krueger L and Stouffer B. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 2012; 58: 130-135.
12. Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, Csajka C and Buclin T. Therapeutic drug monitoring of imatinib: bayesian and alternative methods to predict trough levels. Clinical Pharmacokinetics 2012; 51: 187-201.
13. Götze L, Hegele A, Metzelder SK, Renz H and Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clinica Chimica Acta 2012; 413: 143-149.
14. Guetens G, De Boeck G, Highley M, Dumez H, Van Oosterom and De Bruijn E. Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry. Journal of Chromatography. A 2003; 1020: 27-34.
15. Guilhot F, Hughes T, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C and Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica 2012; 97: 731-738.
16. Haouala A, Zanolari B, Rochat B, Montemurro M, Zaman K, Duchosal MA, Ris HB, Leyvraz S, Widmer N and Decosterd LA. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2009; 877: 1982-1996.
17. Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J and Marin D. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733-3736.
18. Ishikawa Y, Kiyoi H, Watanabe K, Miyamura K, Nakano Y, Kitamura K, Kohno A, Sugiura I, Yokozawa T, Hanamura A, Yamamoto K, Iida H, Emi N, Suzuki R, Ohnishi K and Naoe T. Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Science 2010; 101: 2186-2192.
19. Johnson FM, Agrawal S, Burris H, Rosen L, Dhillon N, Hong D, Blackwood-Chirchir A, Luo FR, Sy O, Kaul S and Chiappori AA. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010; 116: 1582-1591.
20. Kamath AV, Wang J, Lee FY and Marathe PH. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemotherapy and Pharmacology 2008; 61: 365-376.
21. Le Coutre P, Kreuzer K, Pursche S, Bonin M, Leopold T, Baskaynak G, Dorken B, Ehninger G, Ottmann O, Jenke A, Bornhauser M and Schleyer E. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemotherapy and Pharmacology 2004; 53: 313-323.
22. Mičová K, Friedecký D, Faber E, Polýnková A and Adam T. Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Clinica Chimica Acta 2010; 41: 1957-1962.
23. Moen M, McKeage K, Plosker G and Siddiqui A. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67: 299-320.
24. Parise RA, Ramanathan RK, Hayes MJ and Egorin MJ. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2003; 791: 39-44.
25. Peters FT, Drummer OH and Musshoff F. Validation of new methods. Forensic Science International 2007; 165: 216-224.
26. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard M, Lassalle R, Marit G, Reiffers J, Begaud B, Moore N, Molimard M and Mahon F. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukaemia. Blood 2007; 109: 3496-3499.
27. Pirro E, De Francia S, De Martino F, Fava C, Ulisciani S, Cambrin GR, Racca S, Saglio G and Di Carlo F. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. Journal of Chromatographic Science 2011; 49: 753-757.
28. Scheffler M, Di Gion P, Doroshyenko O, Wolf J and Fuhr U. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clinical Pharmacokinetics 2011; 50: 371-403.
29. Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, Le Coutre P, Gruner M, Bornhäuser M, Ottmann OG and Ehninger G. Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2004; 799: 23-36.
30. Singh N, Kumar L, Meena R and Velpandian T. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders. European Journal of Clinical Pharmacology 2009; 65: 545-549.
31. Takahashi N and Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology 2011; 87: 241-248.
32. Takahashi N, Miura M, Niioka T and Sawada K. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients. Cancer Chemotherapy and Pharmacology 2012; 69: 999-1004.
33. Teng JF, Mabasa VH and Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Therapeutic Drug Monitoring 2012; 34: 85-97.
34. Titier K, Picard S, Ducint D, Teilhet E, Moore N, Berthaud P, Mahon FX and Molimard M. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Therapeutic Drug Monitoring 2005; 27: 634-640.
35. von Mehren M and Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treatment Reviews 2011; 37: 291-299.
36. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A and Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer 2006; 94: 1765-1769.
37. Widmer N, Decosterd LA, Leyvraz S, Duchosal MA, Rosselet A, Debiec-Rychter M, Csajka C, Biollaz J and Buclin T. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. British Journal of Cancer 2008; 98: 1633-1640.